(Q34175760)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12573349%20AND%20SRC:MED&resulttype=core&format=json

18 December 2019

review article

1 reference

title

Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12573349%20AND%20SRC:MED&resulttype=core&format=json

18 December 2019

1 reference

1 reference

Carlo Gambacorti-Passerini

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12573349%20AND%20SRC:MED&resulttype=core&format=json

18 December 2019

6

Leonardo Scapozza

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12573349%20AND%20SRC:MED&resulttype=core&format=json

18 December 2019

author name string

Rosalind H Gunby

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12573349%20AND%20SRC:MED&resulttype=core&format=json

18 December 2019

Rocco Piazza

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12573349%20AND%20SRC:MED&resulttype=core&format=json

18 December 2019

Annamaria Galietta

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12573349%20AND%20SRC:MED&resulttype=core&format=json

18 December 2019

Roberta Rostagno

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12573349%20AND%20SRC:MED&resulttype=core&format=json

18 December 2019

publication date

1 February 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12573349%20AND%20SRC:MED&resulttype=core&format=json

Lancet Oncology Commission

18 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12573349%20AND%20SRC:MED&resulttype=core&format=json

18 December 2019

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12573349%20AND%20SRC:MED&resulttype=core&format=json

18 December 2019

page(s)

75-85

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12573349%20AND%20SRC:MED&resulttype=core&format=json

18 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12573349%20AND%20SRC:MED&resulttype=core&format=json

Chronic myeloid leukemia: current treatment options

18 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900979-3

7 January 2021

ARG tyrosine kinase activity is inhibited by STI571.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900979-3

7 January 2021

An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900979-3

7 January 2021

Autoinhibition of c-Abl

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900979-3

7 January 2021

Chronic Myelogenous Leukemia: Disease Biology and Current and Future Therapeutic Strategies.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900979-3

7 January 2021

STI571: a paradigm of new agents for cancer therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900979-3

7 January 2021

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900979-3

7 January 2021

Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900979-3

7 January 2021

In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900979-3

7 January 2021

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900979-3

7 January 2021

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900979-3

7 January 2021

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900979-3

7 January 2021

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900979-3

7 January 2021

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900979-3

7 January 2021

Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900979-3

7 January 2021

Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900979-3

7 January 2021

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900979-3

7 January 2021

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900979-3

7 January 2021

Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900979-3

7 January 2021

Treatment of hypereosinophilic syndrome with imatinib mesilate

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900979-3

7 January 2021

Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900979-3

7 January 2021

Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900979-3

7 January 2021

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900979-3

7 January 2021

Differences between in vivo and in vitro sensitivity to imatinib of Bcr/Abl+ cells obtained from leukemic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900979-3

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900979-3

7 January 2021

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900979-3

7 January 2021

Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900979-3

7 January 2021

Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900979-3

7 January 2021

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900979-3

7 January 2021

Roots of clinical resistance to STI-571 cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900979-3

7 January 2021

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900979-3

7 January 2021

Research on resistance to cancer drug Gleevec

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900979-3

7 January 2021

Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900979-3

7 January 2021

Mechanism-based design of a protein kinase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900979-3

7 January 2021

Crystallographic and solution studies of an activation loop mutant of the insulin receptor tyrosine kinase: insights into kinase mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900979-3

7 January 2021

Adenylate kinase motions during catalysis: an energetic counterweight balancing substrate binding

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900979-3

7 January 2021

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900979-3

7 January 2021

Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900979-3

7 January 2021

Decrease of resistance to imatinib in leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900979-3

7 January 2021

Determination of alpha-1 acid glycoprotein in patients with Ph+ chronic myeloid leukemia during the first 13 weeks of therapy with STI571.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900979-3

7 January 2021

Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900979-3

7 January 2021

Resistance to targeted therapy in leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900979-3

7 January 2021

Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2900979-3

7 January 2021